Hiệu quả và tính an toàn của cangrelor so với ticagrelor ở bệnh nhân nhồi máu cơ tim ST chênh lên (STEMI): một đánh giá hệ thống và phân tích tổng hợp

Franchi F, Rollini F, Angiolillo DJ (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 14(06):361–379

Di Minno MN, Guida A, Camera M, Colli S, Di Minno G, Tremoli E (2011) Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med 43(7):531–544

Droppa M, Geisler T (2018) What is the role of cangrelor in patients undergoing PCI? Curr Vasc Pharmacol 16(5):484–489

Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW et al (2016) CHAMPION PHOENIX Investigators. Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX Trial. JACC Cardiovasc Interv 9(18):1905–1913

Schneider DJ (2016) Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coron Artery Dis 27(1):65–69

Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ et al (2017) International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 136(20):1955–1975

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

Mohammad MA, Andell P, Koul S, James S, Scherstén F, Götberg M, Erlinge D (2017) Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets 28(4):414–416

Franchi F, Ortega-Paz L, Rollini F, Galli M, Been L, Ghanem G, Shalhoub A, Ossi T, Rivas A, Zhou X, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Reiter B, Jilma B, Angiolillo DJ (2023) Cangrelor in patients with coronary artery disease pretreated with Ticagrelor: the switching antiplatelet (SWAP)-5 study. JACC Cardiovasc Interv 16(1):36–46

Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N et al (2019) Cangrelor versus ticagrelor in patients treated with primary percutaneous coronary intervention: impact on platelet activity, myocardial microvascular function and infarct size: a randomized controlled trial. Thromb Haemost 119(7):1171–1181

Badreldin HA, Carter D, Cook BM, Qamar A, Vaduganathan M, Bhatt DL (2017) Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention. Am J Cardiol 120(3):359–361

Rossini R, Masiero G, Fruttero C, Passamonti E, Calvaruso E, Cecconi M, Carlucci C, Mojoli M, Guido P, Talanas G, Pierini S, Canova P, De Cesare N, Luceri S, Barzaghi N, Melloni G, Baralis G, Locatelli A, Musumeci G, Angiolillo DJ (2020) antiplatelet therapy with cangrelor in patients undergoing surgery after coronary stent implantation: a real-world bridging protocol experience. TH Open 4(4):e437–e445

Scalia L, Sammartino S, Greco A, Mauro MS, Calderone D, Agnello F et al (2022) Intravenous cangrelor versus oral ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a propensity score-matched analysis. Eur Heart J. https://doi.org/10.1093/eurheartjsupp/suac121.373

Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M et al (2019) Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139(14):1661–1670

Buchtele N, Herkner H, Schörgenhofer C, Merrelaar A, Laggner R, Gelbenegger G, Spiel AO, Domanovits H, Lang I, Jilma B, Schwameis M (2020) High platelet reactivity after transition from cangrelor to ticagrelor in hypothermic cardiac arrest survivors with ST-segment elevation myocardial infarction. J Clin Med 9(2):583

Westman PC, Lipinski MJ, Torguson R, Waksman R (2017) A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: a network meta-analysis. Cardiovasc Revasc Med 18(2):79–85

Alagna G, Mazzone P, Contarini M, Andò G (2023) Dual antiplatelet therapy with parenteral P2Y12 inhibitors: rationale, evidence, and future directions. J Cardiovasc Dev Dis 10(4):163

Carrick D, Haig C, Ahmed N et al (2016) Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. Circulation 134(23):1833–1847

Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT et al (2020) Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med 180(3):420–428

Coolong A, Mauri L (2006) Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped? Curr Cardiol Rep 8(4):267–271

Fei Y, Lam CK, Cheung BMY (2020) Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep 10:16794

de Barros e Silva PG, Ribeiro HB, Baruzzi AC, Da Silva EE (2016) When is the best time for the second antiplatelet agent in non-ST elevation acute coronary syndrome? Arq Bras Cardiol 106(3):236–246

Layne K, Ferro A (2017) Antiplatelet therapy in acute coronary syndrome. Eur Cardiol 12(1):33–37

Dangas GD, Lincoff AM, White HD, Moses JW, King SB III, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49(1362–1368):13

Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(774–782):14

Manoukian SV (2009) Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST segment elevation myocardial infarction. Am J Cardiol 104:9C-15C

Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV (2007) Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 100:1364–1369

Mathews R, Peterson ED, Honeycutt E, Chin CT, Effron MB, Zettler M et al (2015) Early medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circ Cardiovasc Qual Outcomes 8:347–356

Baroletti S, Dell’orfano H (2010) Medication adherence in cardiovascular disease. Circulation 121:1455–1458

Deharo P, Quilici J, Bonnet G, Pankert M, Verdier V, Morange P, Alessi MC, Bonnet JL, Cuisset T (2014) Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. Int J Cardiol 172:e1–e2